QR Code

New treatment possibilities for rheumatoid arthritis: the Russian experience in using certolizumab pegol

Certolizumab pegol (CZP) is a new drug from the group of tumor necrosis factor a inhibitors. The efficacy and safety CZP in the treatment of rheumatoid arthritis (RA) have been studied in the international 52-week RAPID-1 and 24-week RAPID-2 clinical trials that studied the use of CZP in combination...

Description complète

Enregistré dans:
Auteurs principaux: Dmitry Evgenyevich Karateev, E L Nasonov, L N Denisov, M L Stanislav, E Yu Panasyuk, I A Andrianova, V I Mazurov, E S Zhugrova, Yu P Uspensky, L N Belousova, E P Ilivanova, G K Matsiyevskaya, G P Aurtyunov, K A Lytkina, R S Saikovsky, V N Ardashev, E V Zhilyaev, N I Korshunov
Format: Artigo
Langue:Russo
Publié: IMA PRESS LLC 2012-04-01
Collection:Научно-практическая ревматология
Sujets:
rapid 1
rapid 2
certolizumab pegol
rheumatoid arthritis
randomized clinical trial
Accès en ligne:https://rsp.mediar-press.net/rsp/article/view/1161
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires